Skip to main content
Erschienen in: Current Colorectal Cancer Reports 1/2019

24.01.2019 | Systemic Therapies in Colorectal Cancer (SM Kazmi, Section Editor)

Current Status of Maintenance Systemic Therapies in Metastatic Colorectal Cancer: 2018 Update

verfasst von: Julia Mann, Alexander Stein

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Current systemic management of MCRC includes periods of intensive induction treatment followed by surgery and/or local ablation or maintenance or complete stop. This article is an update of the 2017 review by Quidde et al. and evaluates the most recent data on maintenance strategies in MCRC.

Recent Findings

Induction followed by maintenance and if feasible re-induction treatment does not seem to be inferior to continuous full-dose treatment for patients with MCRC responding to first-line combination regimen but without options for secondary resection or local ablation. Active maintenance seems to be superior to complete stop after at least 3 months of induction treatment in terms of progression-free survival and may add some benefit in terms of OS. The addition of PD-L1 inhibition to maintenance was not effective. The choice of the respective maintenance strategy may be personalised taking into account disease and patient characteristic, choice of induction treatment and response, treatment tolerability and quality of life.

Summary

Patients with MCRC and no options of secondary resection or local ablation should be considered for maintenance treatment.
Literatur
1.
Zurück zum Zitat Global Burden of Disease Cancer, C, et al. The global burden of cancer 2013. JAMA Oncologia. 2015;1(4):505–27.CrossRef Global Burden of Disease Cancer, C, et al. The global burden of cancer 2013. JAMA Oncologia. 2015;1(4):505–27.CrossRef
2.
Zurück zum Zitat Malvezzi M, Carioli G, Bertuccio P, Rosso T, Boffetta P, Levi F, et al. European cancer mortality predictions for the year 2016 with focus on leukaemias. Ann Oncol. 2016;27(4):725–31.CrossRefPubMed Malvezzi M, Carioli G, Bertuccio P, Rosso T, Boffetta P, Levi F, et al. European cancer mortality predictions for the year 2016 with focus on leukaemias. Ann Oncol. 2016;27(4):725–31.CrossRefPubMed
3.
Zurück zum Zitat Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.CrossRefPubMed Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.CrossRefPubMed
4.
Zurück zum Zitat • Van Cutsem E, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. The ESMO consensus guidelines have been developed based on the current available evidence to provide a series of expert recommendations to assist in the treatment and management of patients with metastatic colorectal cancer in this rapidly evolving treatment setting. CrossRefPubMed • Van Cutsem E, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. The ESMO consensus guidelines have been developed based on the current available evidence to provide a series of expert recommendations to assist in the treatment and management of patients with metastatic colorectal cancer in this rapidly evolving treatment setting. CrossRefPubMed
5.
Zurück zum Zitat Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91.CrossRefPubMedPubMedCentral Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Overman MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–9 JCO2017769901.CrossRefPubMed Overman MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–9 JCO2017769901.CrossRefPubMed
8.
Zurück zum Zitat Kopetz ES, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol. 2017;35(suppl 4S):abstract 520.CrossRef Kopetz ES, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol. 2017;35(suppl 4S):abstract 520.CrossRef
9.
Zurück zum Zitat Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738–46.CrossRefPubMed Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738–46.CrossRefPubMed
10.
Zurück zum Zitat Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018;36(6):536–42.CrossRefPubMed Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018;36(6):536–42.CrossRefPubMed
11.
Zurück zum Zitat Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–15.CrossRefPubMed Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–15.CrossRefPubMed
12.
Zurück zum Zitat Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34.CrossRefPubMed Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34.CrossRefPubMed
13.
Zurück zum Zitat Van Cutsem E, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33(7):692–700.CrossRefPubMed Van Cutsem E, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33(7):692–700.CrossRefPubMed
14.
Zurück zum Zitat Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75.CrossRefPubMed Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75.CrossRefPubMed
15.
Zurück zum Zitat Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.CrossRefPubMed Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.CrossRefPubMed
16.
Zurück zum Zitat Quidde J, Stein A. Personalizing maintenance therapy in metastatic colorectal cancer. Curr Colorectal Cancer Reports. 2017;13(3):205–11.CrossRef Quidde J, Stein A. Personalizing maintenance therapy in metastatic colorectal cancer. Curr Colorectal Cancer Reports. 2017;13(3):205–11.CrossRef
17.
Zurück zum Zitat Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet. 2003;361(9356):457–64.CrossRefPubMed Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet. 2003;361(9356):457–64.CrossRefPubMed
18.
Zurück zum Zitat Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011;12(7):642–53.CrossRefPubMedPubMedCentral Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011;12(7):642–53.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol. 2006;24(3):394–400.CrossRefPubMed Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol. 2006;24(3):394–400.CrossRefPubMed
20.
Zurück zum Zitat Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Nicolella D, et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol. 2011;22(5):1236–42.CrossRefPubMed Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Nicolella D, et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol. 2011;22(5):1236–42.CrossRefPubMed
21.
Zurück zum Zitat Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol. 2009;27(34):5727–33.CrossRefPubMed Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol. 2009;27(34):5727–33.CrossRefPubMed
22.
Zurück zum Zitat Diaz-Rubio E, Gomez-Espana A, Massuti B, Sastre J, Abad A, Valladares M, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012;17(1):15–25.CrossRefPubMedPubMedCentral Diaz-Rubio E, Gomez-Espana A, Massuti B, Sastre J, Abad A, Valladares M, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012;17(1):15–25.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'stop-and-go' study results--a Turkish oncology group trial. Oncology. 2013;85(6):328–35.CrossRefPubMed Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'stop-and-go' study results--a Turkish oncology group trial. Oncology. 2013;85(6):328–35.CrossRefPubMed
24.
Zurück zum Zitat Hochster HS, Grothey A, Hart L, Rowland K, Ansari R, Alberts S, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol. 2014;25(6):1172–8.CrossRefPubMedPubMedCentral Hochster HS, Grothey A, Hart L, Rowland K, Ansari R, Alberts S, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol. 2014;25(6):1172–8.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Pfeiffer P, Sorbye H, Qvortrup C, Karlberg M, Kersten C, Vistisen K, et al. Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: the NORDIC-7.5 study by the Nordic colorectal cancer biomodulation group. Clin Colorectal Cancer. 2015;14(3):170–6.CrossRefPubMed Pfeiffer P, Sorbye H, Qvortrup C, Karlberg M, Kersten C, Vistisen K, et al. Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: the NORDIC-7.5 study by the Nordic colorectal cancer biomodulation group. Clin Colorectal Cancer. 2015;14(3):170–6.CrossRefPubMed
26.
Zurück zum Zitat Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012;30(15):1755–62.CrossRefPubMed Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012;30(15):1755–62.CrossRefPubMed
27.
Zurück zum Zitat Simkens LH, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385(9980):1843–52. Simkens LH, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385(9980):1843–52.
28.
Zurück zum Zitat Koeberle D, Betticher DC, von Moos R, Dietrich D, Brauchli P, Baertschi D, et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol. 2015;26(4):709–14.CrossRefPubMed Koeberle D, Betticher DC, von Moos R, Dietrich D, Brauchli P, Baertschi D, et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol. 2015;26(4):709–14.CrossRefPubMed
29.
Zurück zum Zitat Hegewisch-Becker S, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015;16(13):1355–69. Hegewisch-Becker S, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015;16(13):1355–69.
30.
Zurück zum Zitat Aparicio T, Ghiringhelli F, Boige V, le Malicot K, Taieb J, Bouché O, et al. Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9). J Clin Oncol. 2018;36(7):674–81.CrossRefPubMed Aparicio T, Ghiringhelli F, Boige V, le Malicot K, Taieb J, Bouché O, et al. Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9). J Clin Oncol. 2018;36(7):674–81.CrossRefPubMed
31.
Zurück zum Zitat Goey KKH, Elias SG, Hinke A, van Oijen MGH, Punt CJA, Hegewisch-Becker S, et al. Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials. Br J Cancer. 2017;117(12):1768–76.CrossRefPubMedPubMedCentral Goey KKH, Elias SG, Hinke A, van Oijen MGH, Punt CJA, Hegewisch-Becker S, et al. Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials. Br J Cancer. 2017;117(12):1768–76.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Stein A, Schwenke C, Folprecht G, Arnold D. Effect of application and intensity of Bevacizumab-based maintenance after induction chemotherapy with Bevacizumab for metastatic colorectal Cancer: a meta-analysis. Clin Colorectal Cancer. 2016;15(2):e29–39.CrossRefPubMed Stein A, Schwenke C, Folprecht G, Arnold D. Effect of application and intensity of Bevacizumab-based maintenance after induction chemotherapy with Bevacizumab for metastatic colorectal Cancer: a meta-analysis. Clin Colorectal Cancer. 2016;15(2):e29–39.CrossRefPubMed
33.
Zurück zum Zitat Wasan H, Meade AM, Adams R, Wilson R, Pugh C, Fisher D, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol. 2014;15(6):631–9.CrossRefPubMedPubMedCentral Wasan H, Meade AM, Adams R, Wilson R, Pugh C, Fisher D, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol. 2014;15(6):631–9.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Aranda E, García-Alfonso P, Benavides M, Sánchez Ruiz A, Guillén-Ponce C, Safont MJ, et al. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: phase II randomised MACRO2 TTD study. Eur J Cancer. 2018;101:263–72.CrossRefPubMed Aranda E, García-Alfonso P, Benavides M, Sánchez Ruiz A, Guillén-Ponce C, Safont MJ, et al. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: phase II randomised MACRO2 TTD study. Eur J Cancer. 2018;101:263–72.CrossRefPubMed
35.
Zurück zum Zitat Pietrantonio F, Morano F, Corallo S. First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. J Clin Oncol. 2018;36(suppl):abstr 3505.CrossRef Pietrantonio F, Morano F, Corallo S. First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. J Clin Oncol. 2018;36(suppl):abstr 3505.CrossRef
36.
Zurück zum Zitat Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mésange P, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2015;16(15):1493–505.CrossRefPubMed Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mésange P, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2015;16(15):1493–505.CrossRefPubMed
37.
Zurück zum Zitat Johnsson A, Hagman H, Frödin JE, Berglund Å, Keldsen N, Fernebro E, et al. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. Ann Oncol. 2013;24(9):2335–41.CrossRefPubMed Johnsson A, Hagman H, Frödin JE, Berglund Å, Keldsen N, Fernebro E, et al. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. Ann Oncol. 2013;24(9):2335–41.CrossRefPubMed
38.
Zurück zum Zitat Schmoll HJ, Arnold D, de Gramont A, Ducreux M, Grothey A, O’Dwyer PJ, et al. MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. J Cancer Res Clin Oncol. 2018;144(6):1197–204.CrossRefPubMed Schmoll HJ, Arnold D, de Gramont A, Ducreux M, Grothey A, O’Dwyer PJ, et al. MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. J Cancer Res Clin Oncol. 2018;144(6):1197–204.CrossRefPubMed
39.
Zurück zum Zitat Grothey A, Tabernero J, Arnold D. Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL. Presented at ESMO 2018. Ann Oncol. 2018; suppl(proffered paper). Grothey A, Tabernero J, Arnold D. Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL. Presented at ESMO 2018. Ann Oncol. 2018; suppl(proffered paper).
40.
Zurück zum Zitat Bendell JC, Ciardiello F, Tabernero J. Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. Ann Oncol. 2018;29(suppl 5):LBA-004. Bendell JC, Ciardiello F, Tabernero J. Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. Ann Oncol. 2018;29(suppl 5):LBA-004.
41.
Zurück zum Zitat Schmoll HJ, Wittig B, Arnold D, Riera-Knorrenschild J, Nitsche D, Kroening H, et al. Maintenance treatment with the immunomodulator MGN1703, a toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014;140:1615–24.CrossRefPubMedPubMedCentral Schmoll HJ, Wittig B, Arnold D, Riera-Knorrenschild J, Nitsche D, Kroening H, et al. Maintenance treatment with the immunomodulator MGN1703, a toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014;140:1615–24.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Goey KKH, Elias SG, Van Tinteren H. Predictive value of KRAS mutation status in metastatic colorectal cancer (mCRC) patients treated with capecitabine and bevacizumab (CAP-B) maintenance treatment vs observation in the phase III CAIRO3 study. J Clin Oncol. 2016;34(suppl):abstr 3525.CrossRef Goey KKH, Elias SG, Van Tinteren H. Predictive value of KRAS mutation status in metastatic colorectal cancer (mCRC) patients treated with capecitabine and bevacizumab (CAP-B) maintenance treatment vs observation in the phase III CAIRO3 study. J Clin Oncol. 2016;34(suppl):abstr 3525.CrossRef
43.
Zurück zum Zitat Noepel-Duennebacke S, Arnold D, Hertel J, Tannapfel A, Hinke A, Hegewisch-Becker S, et al. Impact of the localization of the primary tumor and RAS/BRAF mutational status on maintenance strategies after first-line oxaliplatin, fluoropyrimidine, and bevacizumab in metastatic colorectal cancer: results from the AIO 0207 trial. Clin Colorectal Cancer. 2018;17:e733–9.CrossRefPubMed Noepel-Duennebacke S, Arnold D, Hertel J, Tannapfel A, Hinke A, Hegewisch-Becker S, et al. Impact of the localization of the primary tumor and RAS/BRAF mutational status on maintenance strategies after first-line oxaliplatin, fluoropyrimidine, and bevacizumab in metastatic colorectal cancer: results from the AIO 0207 trial. Clin Colorectal Cancer. 2018;17:e733–9.CrossRefPubMed
44.
Zurück zum Zitat Stein A, Binder M, Al-Batran SE. Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216). J Clin Oncol. 2018;36(15 suppl):3561.CrossRef Stein A, Binder M, Al-Batran SE. Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216). J Clin Oncol. 2018;36(15 suppl):3561.CrossRef
45.
Zurück zum Zitat • Quidde J, et al. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. Ann Oncol. 2016;27(12):2203–10. This was one of the first studies analyzing quality of life during maintenance treatment. The study showed that continuation of an active maintenance treatment with fluoropyrimidine and bevacizumab after induction treatment was neither associated with a detrimental effect on health-related quality of life when compared to bevacizumab alone or no active treatment. CrossRefPubMed • Quidde J, et al. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. Ann Oncol. 2016;27(12):2203–10. This was one of the first studies analyzing quality of life during maintenance treatment. The study showed that continuation of an active maintenance treatment with fluoropyrimidine and bevacizumab after induction treatment was neither associated with a detrimental effect on health-related quality of life when compared to bevacizumab alone or no active treatment. CrossRefPubMed
46.
Zurück zum Zitat • Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44–70. The ESMO consensus guidelines have been developed based on the current available evidence to provide a series of expert recommendations to assist in the treatment and management of patients with metastatic colorectal cancer in this rapidly evolving treatment setting. • Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44–70. The ESMO consensus guidelines have been developed based on the current available evidence to provide a series of expert recommendations to assist in the treatment and management of patients with metastatic colorectal cancer in this rapidly evolving treatment setting.
Metadaten
Titel
Current Status of Maintenance Systemic Therapies in Metastatic Colorectal Cancer: 2018 Update
verfasst von
Julia Mann
Alexander Stein
Publikationsdatum
24.01.2019
Verlag
Springer US
Erschienen in
Current Colorectal Cancer Reports / Ausgabe 1/2019
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-019-00426-2

Weitere Artikel der Ausgabe 1/2019

Current Colorectal Cancer Reports 1/2019 Zur Ausgabe

Surgery and Surgical Innovations in Colorectal Cancer (S Huerta, Section Editor)

A Surgeon’s Guide to Treating Older Patients With Colorectal Cancer

Surgery and Surgical Innovations in Colorectal Cancer (S Huerta, Section Editor)

Techniques for Colorectal Anastomotic Construction Following Proctectomy and Variables Influencing Anastomotic Leak

Surgery and Surgical Innovations in Colorectal Cancer (S Huerta, Section Editor)

Current Surgical Strategies in the Management of Rectal Cancer

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.